Phio Pharmaceuticals Corp. (PHIO) Stock Score, Valuation & Financial Research

Phio Pharmaceuticals Corp. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PHIO

Phio Pharmaceuticals Corp. does not currently have a complete Wall Street Score. The stored market price is USD 0.95. These figures are a research snapshot, not a buy or sell recommendation.

What Phio Pharmaceuticals Corp. does

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Phio Pharmaceuticals is a clinical-stage biopharmaceutical company that has not yet generated commercial product revenue. Its business model focuses on the research and development of its proprietary INTASYL small interfering RNA gene silencing technology, which is designed to enhance the effectiveness of immune cells in killing tumor cells.

Products and services

  • The company is developing immuno-oncology therapeutics, specifically its INTASYL platform, with lead candidates such as PH-762 designed for direct-to-tumor application to inhibit tumor growth.

Brands and product families

  • INTASYL — Proprietary small interfering RNA gene silencing technology platform. Source

Customer types

Clinical trial patients.

Business strengths to evaluate

  • Proprietary INTASYL small interfering RNA gene silencing technology platform Source

Business risks and research considerations

  • History of operating losses and no commercial product revenue Source
  • Dependence on clinical trial success and patient enrollment Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PHIO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.95
Market capitalization:
11.08M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -12.9M
Free cash flow:
USD -7.99M
Cash:
USD 13M
Total debt:
USD 0.00
EPS:
USD -1.34

What stands out

  • Free cash flow is USD -7.99M, negative for the stored period.
  • The balance sheet shows USD 13M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 13M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PHIO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PHIO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PHIO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PHIO to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PHIO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research PHIO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.